{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:11:09Z","timestamp":1792631469918,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":3688,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (&amp;lt;35%), and at high risk for recurrent HF-related events, despite optimal medical therapy, will be randomized 1:1 to receive 600\u2009\u00d7\u2009106 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF.<\/jats:p>\n                    <jats:p>Trial registration: NCT01768702<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.434","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T03:12:56Z","timestamp":1450062776000},"page":"160-168","source":"Crossref","is-referenced-by-count":80,"title":["Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Trial Design"],"prefix":"10.1093","volume":"18","author":[{"given":"Jozef","family":"Bartunek","sequence":"first","affiliation":[{"name":"Cardiovascular Centre, OLV Hospital , Aalst ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Davison","sequence":"additional","affiliation":[{"name":"Momentum Research Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Sherman","sequence":"additional","affiliation":[{"name":"Celyad S.A. , Mont Saint Guibert ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Povsic","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[{"name":"Cedars Sinai Heart Institute , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gersh","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine, Division of Cardiovascular Diseases, Department of Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Athens University Hospital , Attikon ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atta","family":"Behfar","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine, Division of Cardiovascular Diseases, Department of Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Homsy","sequence":"additional","affiliation":[{"name":"Celyad S.A. , Mont Saint Guibert ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, OLV Hospital , Aalst ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tendera","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Terzic","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine, Division of Cardiovascular Diseases, Department of Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"2026011721135886800_ejhf434-bib-0001","first-page":"e29","article-title":"Heart Disease and Stroke Statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"2026011721135886800_ejhf434-bib-0002","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","article-title":"The war against heart failure; the Lancet lecture","volume":"385","author":"Braunwald","year":"2014","journal-title":"Lancet"},{"key":"2026011721135886800_ejhf434-bib-0003","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/hrt.2007.139394","article-title":"Cells as biologics for cardiac repair in ischaemic heart failure","volume":"96","author":"Bartunek","year":"2010","journal-title":"Heart"},{"key":"2026011721135886800_ejhf434-bib-0004","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006681","article-title":"Strategies for cardiac regeneration and repair","volume":"6","author":"Lin","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026011721135886800_ejhf434-bib-0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","article-title":"Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions","volume":"113","author":"Sanganalmath","year":"2013","journal-title":"Circ Res"},{"key":"2026011721135886800_ejhf434-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000338","article-title":"The advancing field of cell-based therapy: insights and lessons from clinical trials","volume":"2","author":"Telukuntla","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026011721135886800_ejhf434-bib-0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/HCO.0000000000000138","article-title":"Stem cells in the management of advanced heart failure","volume":"30","author":"Menasch\u00e9","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0008","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehu117","article-title":"Regenerative heart failure therapy headed for optimization","volume":"35","author":"Terzic","year":"2014","journal-title":"Eur Heart J."},{"key":"2026011721135886800_ejhf434-bib-0009","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/CIRCULATIONAHA.111.086074","article-title":"Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis","volume":"126","author":"Jeevanantham","year":"2012","journal-title":"Circulation."},{"key":"2026011721135886800_ejhf434-bib-0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007888.pub2","article-title":"Stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"4","author":"Fisher","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011721135886800_ejhf434-bib-0011","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrcardio.2014.9","article-title":"Cell therapy for cardiac repair: lessons from clinical trials","volume":"11","author":"Behfar","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0012","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCRESAHA.115.304353","article-title":"Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes","volume":"115","author":"Cogle","year":"2014","journal-title":"Circ Res"},{"key":"2026011721135886800_ejhf434-bib-0013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2014.10.041","article-title":"Stem cells versus senescence: the yin and yang of cardiac health","volume":"65","author":"Behfar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0014","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/CIRCRESAHA.114.305075","article-title":"Stem cell in the rough: repair quotient mined out of a bone marrow niche","volume":"115","author":"Behfar","year":"2014","journal-title":"Circ Res"},{"key":"2026011721135886800_ejhf434-bib-0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jacc.2010.03.066","article-title":"Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction","volume":"56","author":"Behfar","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0016","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2013.02.071","article-title":"Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics","volume":"61","author":"Bartunek","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0017","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1054\/jcaf.2001.25652","article-title":"Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure","volume":"7","author":"Packer","year":"2001","journal-title":"J Card Fail"},{"key":"2026011721135886800_ejhf434-bib-0018","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat Med"},{"key":"2026011721135886800_ejhf434-bib-0019","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan multicenter research group","volume":"124","author":"Rector","year":"1992","journal-title":"Am Heart J"},{"key":"2026011721135886800_ejhf434-bib-0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/CIRCINTERVENTIONS.112.000422","article-title":"Optimized delivery system achieves enhanced endomyocardial stem cell retention","volume":"6","author":"Behfar","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"2026011721135886800_ejhf434-bib-0021","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation"},{"key":"2026011721135886800_ejhf434-bib-0022","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ahj.2011.07.020","article-title":"A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction","volume":"162","author":"Povsic","year":"2011","journal-title":"Am Heart J"},{"key":"2026011721135886800_ejhf434-bib-0023","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-a165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study\u2014The Euroinject One trial","volume":"45","author":"Kastrup","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0024","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721135886800_ejhf434-bib-0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2014.05.021","article-title":"Current challenges for clinical trials of cardiovascular medical devices","volume":"175","author":"Zannad","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026011721135886800_ejhf434-bib-0026","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/eurjhf\/hft095","article-title":"Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document","volume":"15","author":"Zannad","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721135886800_ejhf434-bib-0027","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1388-9842(02)00006-5","article-title":"Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the Epical study","volume":"4","author":"Alla","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2026011721135886800_ejhf434-bib-0028","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011721135886800_ejhf434-bib-0029","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10976640009148691","article-title":"Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance","volume":"2","author":"Bellenger","year":"2000","journal-title":"J Cardiovasc Magn Res"},{"key":"2026011721135886800_ejhf434-bib-0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/eurheartj\/ehq427","article-title":"One year follow-up of the multi-centre European Partner Transcatheter Heart Valve study","volume":"32","author":"Lefevre","year":"2011","journal-title":"Eur Heart J"},{"key":"2026011721135886800_ejhf434-bib-0031","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurheartj\/ehu205","article-title":"The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials","volume":"35","author":"Anker","year":"2014","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.434","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.434","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/2\/160\/66380131\/eurjhf_18_2_160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/2\/160\/66380131\/eurjhf_18_2_160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:14:21Z","timestamp":1768702461000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/2\/160\/8423180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,12,14]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.434","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2015,12,14]]}}}